All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Neuralstem Inc., of Germantown, Md., said it completed enrollment in its phase II trial of small-molecule NSI-189 for the treatment of major depressive disorder.